Well, there is very little monitoring going on there, and I've suggested in the past at consultations with Health Canada that what we really need is a pharmaco-vigilance program around the medical cannabis program that would allow the tracking of patients.
I had a recent conversation with Dr. Mark Ware, who is president of the Canadian Consortium for the Investigation of Cannabinoids, and I understand that he and the Quebec government have an agreement to track all Quebec patients in terms of looking at their use through their physicians. That is going to be ongoing and it is something that we can certainly look at down the road as more of a national study.
Now, it's not unusual at all for us to have thousands of Canadians on different prescription drugs without doing active monitoring of what's happening with each patient.